Cargando…

Long-Term Improvement in a Chinese Cohort of Glucocorticoid-Resistant Childhood-Onset Myasthenia Gravis Patients Treated With Tacrolimus

OBJECTIVES: To evaluate the long-term outcome of tacrolimus for childhood-onset myasthenia gravis (CMG) with an inadequate response to glucocorticoids, and investigate factors associated with favorable outcomes following tacrolimus treatment. METHODS: A retrospective, observational cohort study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bi, Zhuajin, Cao, Yayun, Lin, Jing, Zhang, Qing, Liu, Chenchen, Gui, Mengcui, Bu, Bitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860838/ https://www.ncbi.nlm.nih.gov/pubmed/35211085 http://dx.doi.org/10.3389/fneur.2022.820205

Ejemplares similares

Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort
por: Bi, Zhuajin, et al.
Publicado: (2022)

Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation
por: Zhang, Qing, et al.
Publicado: (2022)

Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis
por: Bi, Zhuajin, et al.
Publicado: (2022)

Polymorphisms in drug metabolism genes predict the risk of refractory myasthenia gravis
por: Zhang, Qing, et al.
Publicado: (2022)

Guillain-Barré syndrome associated with myasthenia gravis: Three cases report and a literature review
por: Cao, Yayun, et al.
Publicado: (2019)

Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis
por: Bi, Zhuajin, et al.
Publicado: (2023)

Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis
por: Zheng, Yiming, et al.
Publicado: (2022)

Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
por: Fan, Zhirong, et al.
Publicado: (2020)

Myasthenia Gravis with Elderly Onset at Advanced Age
por: Hernandez Fustes, Otto Jesus, et al.
Publicado: (2020)

Upregulation of circ‐FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR‐133/PAX7
por: Lai, Xiaoyin, et al.
Publicado: (2021)

Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis
por: Fan, Zhirong, et al.
Publicado: (2023)

Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)

Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient
por: Huber, Meret, et al.
Publicado: (2020)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Efficacy of tacrolimus as long-term immunotherapy for neuronal surface antibody-mediated autoimmune encephalitis
por: Liu, Chenchen, et al.
Publicado: (2022)

Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China
por: Zhou, Lei, et al.
Publicado: (2017)

Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020)

Management of Juvenile Myasthenia Gravis
por: O'Connell, Karen, et al.
Publicado: (2020)

Controversies in Ocular Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2020)

Immunoregulatory Cells in Myasthenia Gravis
por: Wu, Ying, et al.
Publicado: (2020)

Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)

Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Molecular and clinical relationship between live‐attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis
por: He, Dan, et al.
Publicado: (2018)

Increased expression of cell adhesion molecules in myofasciitis
por: Ma, Xue, et al.
Publicado: (2023)

The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review
por: Heckmann, Jeannine M., et al.
Publicado: (2022)

Vitamin D Receptor Polymorphism and Myasthenia Gravis in Chinese Han Population
por: Han, Ji-Lan, et al.
Publicado: (2021)

Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022)

User Involvement in Myasthenia Gravis Research
por: Gilhus, Nils Erik, et al.
Publicado: (2022)

Myasthenia Gravis Presenting as Bulbar Palsy
por: Gosain, Dhruv, et al.
Publicado: (2023)

Patients With Myasthenia Gravis With Acute Onset of Dyspnea: Predictors of Progression to Myasthenic Crisis and Prognosis
por: Huang, Yangyu, et al.
Publicado: (2021)

New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine
por: Abicic, Ana, et al.
Publicado: (2022)

Treatment of insomnia in myasthenia gravis—A prospective study on non-benzodiazepine hypnotics in the treatment of myasthenia gravis patients with insomnia
por: Yan, Jingwen, et al.
Publicado: (2023)

Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset
por: Zhao, Sijia, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis
por: Kim, Yool-hee, et al.
Publicado: (2019)

Determinants of Quality of Life in Myasthenia Gravis Patients
por: Szczudlik, Piotr, et al.
Publicado: (2020)

A Review of Psychiatric Comorbidity in Myasthenia Gravis
por: Law, Christina, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020)

Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
por: Imai, Tomihiro, et al.
Publicado: (2020)

The Muscle Is Not a Passive Target in Myasthenia Gravis
por: Vilquin, Jean-Thomas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_evr7vtj761egsgdr3o92qogrip